{{Use dmy dates|date=May 2011}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 457287206
| IUPAC_name = 2-<nowiki/>{3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-''a'']pyridin-3(2''H'')-one
| image = Trazodone.svg
| width = 250px
| image2 = Trazodone-from-HCl-xtal-3D-balls.png
| width2 = 250px

<!--Clinical data-->
| tradename = Many brand names worldwide<ref name=genericnames/>
| Drugs.com = {{drugs.com|monograph|trazodone-hydrochloride}}
| MedlinePlus = a681038
| pregnancy_US = C
| legal_US = Rx-only
| legal_UK = POM
| legal_AU = S4
| legal_CA = Rx-only
| routes_of_administration = [[Oral administration|By mouth]] ([[Tablet (pharmacy)|tablets]])

<!--Pharmacokinetic data-->
| bioavailability = [[Oral administration|Oral]]: 65%<ref name="DrugPoint">Truven Health Analytics, Inc. DrugPoint System (Internet) [cited 2013 Oct 1]. Greenwood Village, CO: Thomsen Healthcare; 2013. {{Failed verification|date=April 2017|reason=search for "Trazodone" fails on Truven Web site}}</ref>
| protein_bound = 89–95%<ref>{{cite web|url=http://www.drugbank.ca/drugs/DB00656| title=Trazodone|website=DrugBank|accessdate=7 June 2015}}</ref>
| metabolism = [[Liver|Hepatic]] ([[CYP3A4]])<ref name="DrugPoint" />
| metabolites = {{abbrlink|mCPP|meta-Chlorophenylpiperazine}}<ref name="PreskornStanga2012">{{cite book|author1=Sheldon H. Preskorn|author2=Christina Y. Stanga|author3=John P. Feighner|author4=Ruth Ross|title=Antidepressants: Past, Present and Future|url=https://books.google.com/books?id=Ue3uCAAAQBAJ&pg=PA68|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-18500-7|pages=68–}}</ref>
| onset = [[Oral administration|Oral]]: 1 hour ([[Tmax (pharmacology)|{{abbr|T<sub>max</sub>|Time to peak concentrations}}]])<ref>{{cite web |url=http://www.pharmacychoice.com/mdx/drugpoint.cfm?docID=622860&letter=T&type=Generic%20Name |title=MicroMedex DrugPoints - Trazodone|website=Pharmacy Choice|date= |author= |accessdate= 20 April 2017}}</ref>
| elimination_half-life = Trazodone {{abbr|IR|immediate-release}}: 7 hours<ref name="DrugPoint" /><br />Trazodone {{abbr|ER|extended-release}}: 10 hours<ref name="DrugPoint" /><br />{{abbrlink|mCPP|meta-Chlorophenylpiperazine}}: 4–8 hours<ref name="SchatzbergNemeroff2017">{{cite book|author1=Alan F. Schatzberg, M.D.|author2=Charles B. Nemeroff, M.D., Ph.D.|title=The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition|url=https://books.google.com/books?id=KfHEDgAAQBAJ&pg=PA460|year=2017|publisher=American Psychiatric Pub|isbn=978-1-58562-523-9|pages=460–}}</ref>
| excretion = [[Urine]]: 70–75%<ref name="DrugPoint" /><br />[[Feces]]: 21%<ref name="DrugPoint" />

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 19794-93-5
| ATC_prefix = N06
| ATC_suffix = AX05
| PubChem = 5533
| IUPHAR_ligand = 213
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00656
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5332
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = YBK48BXK30
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08626
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 9654
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 621

<!--Chemical data-->
| C=19 | H=22 | Cl=1 | N=5 | O=1
| molecular_weight = 371.8641 g/mol
| SMILES = Clc4cccc(N3CCN(CCCN1/N=C2/C=C\C=C/N2C1=O)CC3)c4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PHLBKPHSAVXXEF-UHFFFAOYSA-N
}}

'''Trazodone''', sold under the brand name '''Oleptro''' among others,<ref name=genericnames>[http://www.drugs.com/international/trazodone.html Drugs.com international listings for Trazodone] Page accessed Feb 10, 2016</ref> is an [[antidepressant]] of the [[serotonin antagonist and reuptake inhibitor]] (SARI) class. It is a [[phenylpiperazine]] compound. Trazodone also has anti-anxiety ([[anxiolytic]]) and sleep-inducing ([[hypnotic]]) effects.<ref>{{cite journal |vauthors=Haria M, Fitton A, McTavish D |title=Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders |journal=Drugs Aging |volume=4 |issue=4 |pages=331–55 |date=April 1994|pmid=8019056 |doi=10.2165/00002512-199404040-00006 }}</ref> Its side-effect profile and potential toxicity are considerably different from those of the original antidepressants (i.e., the [[monoamine oxidase inhibitor]]s (MAOIs) and [[tricyclic antidepressant]]s (TCAs)).<ref name="Textbook of Psychopharmacology">{{cite book |editor1-last=Schatzberg |editor1-first=AF |editor2-last=Nemeroff |editor2-first=CB |title=Textbook of Psychopharmacology |edition=4th |year=2009 |publisher= American Psychiatric Publishing |location=Washington, D.C. |isbn=978-1-58562-309-9}}</ref>

{{TOC limit|3}}

==Medical uses==
Trazodone has the following medical uses:

* [[Unipolar depression]], with or without anxiety<ref>{{cite web|title=Desyrel – FDA Prescribing Information|url=http://www.drugs.com/pro/desyrel.html|website=Drugs.com|accessdate=4 June 2015}}</ref>
* [[Anxiety disorder]]<ref name = "BNF 65">{{cite book|title=British National Formulary (BNF) 65|year=2013|publisher=Pharmaceutical Press|location=London, UK|isbn=9780857110848|page=247}}</ref>
* [[Insomnia]]<ref>{{cite journal |vauthors=Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M |title=Trazodone for antidepressant-associated insomnia |journal=Am J Psychiatry |volume=151 |issue=7 |pages=1069–72 |date=July 1994|pmid=8010365 |url=http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=8010365 |doi=10.1176/ajp.151.7.1069}}</ref><ref>{{cite journal |vauthors=Kaynak H, Kaynak D, Gözükirmizi E, Guilleminault C |title=The effects of trazodone on sleep in patients treated with stimulant antidepressants |journal=Sleep Med. |volume=5 |issue=1 |pages=15–20 |date=January 2004|pmid=14725822 |url=http://linkinghub.elsevier.com/retrieve/pii/S1389945703002065 |doi=10.1016/j.sleep.2003.06.006}}</ref><ref>{{cite journal |vauthors=Scharf MB, Sachais BA |title=Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients |journal=J Clin Psychiatry |volume=51 |issue=Suppl |pages=13–7 |date=September 1990 |pmid=2211559 }}</ref> (in some countries, e.g., the Czech Republic and the EU in general)

The primary use of trazodone is the treatment of major depression. Data from open and [[double-blind trial]]s suggest the antidepressant efficacy of trazodone is comparable to that of [[amitriptyline]], [[doxepin]], and [[mianserin]]. Also, trazodone showed [[anxiolytic]] properties, low [[cardiotoxicity]], and relatively mild side effects.<ref name="Textbook of Psychopharmacology" />

Because trazodone has minimal [[anticholinergic]] activity, it was especially welcomed as a treatment for geriatric patients with depression when it first became available. Three double-blind studies reported trazodone has antidepressant efficacy similar to that of other antidepressants in geriatric patients. However, a side effect of trazodone, [[orthostatic hypotension]], which may cause dizziness and increase the risk of falling, can have devastating consequences for elderly patients; thus, this side effect, along with sedation, often makes trazodone less acceptable for this population, compared with newer compounds that share its lack of anticholinergic activity but not the rest of its side-effect profile. Still, trazodone is often helpful for geriatric patients with depression who have severe agitation and insomnia.<ref name="Textbook of Psychopharmacology" />

Trazodone has also been reported to have [[anxiolytic|antianxiety properties]]. In a randomized, double-blind, [[placebo-controlled trial]], the anxiolytic efficacy of trazodone was comparable to that of [[diazepam]] in weeks 3–8 of treatment for generalized [[anxiety disorder]], although patients treated with [[diazepam]] had greater improvement during the first 2 weeks of treatment.<ref name="Rickels K, Downing R, Schweizer E, Hassman H 1993 884–95" />

Early case reports had indicated that trazodone is associated with improvement in [[obsessive-compulsive disorder]], but a double-blind, placebo-controlled study found that trazodone lacked [[antiobsessional]] effects.<ref name="Pigott TA, L'Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL 1992 156–62" />

Many clinicians use low-dose trazodone as an alternative to [[benzodiazepines]] for the treatment of [[insomnia]]. Two recent reviews found that trazodone is the second most prescribed agent for [[insomnia]], but as most studies have been limited to patients with [[Major depressive disorder|depression]], few studies actually support trazodone's use in primary insomnia.<ref name="Textbook of Psychopharmacology" />

===Non-approved uses===
[[Off-label]], or non-[[Food and Drug Administration|FDA]] approved, uses and [[Investigational New Drug|investigational]] uses are listed below:

* [[Fibromyalgia]]<ref>{{Cite journal | last1 = Morillas-Arques | first1 = P. | last2 = Rodriguez-Lopez | first2 = C. | last3 = Molina-Barea | first3 = R. | last4 = Rico-Villademoros | first4 = F. | last5 = Calandre | first5 = E. P. | title = Trazodone for the treatment of fibromyalgia: An open-label, 12-week study | doi = 10.1186/1471-2474-11-204 | journal = BMC Musculoskeletal Disorders | volume = 11 | pages = 204 | year = 2010 | pmid = 20831796| pmc =2945951 }}</ref>
* [[Complex regional pain syndrome]]<ref>{{cite web|url=http://www.medscape.com/viewarticle/704976_2 |title=Understanding the Pharmacologic Therapy for Complex Regional Pain Syndrome: Pharmacologic Therapy |publisher=Medscape.com |accessdate=2014-03-14}}</ref>
* Control of nightmares<ref>{{Cite journal | last1=Warner, | first1= M. D., | last2=Dorn, | first2= M. R., | last3=Peabody | first3= C. A., | title=Survey on the Usefulness of Trazodone in Patients with PTSD with Insomnia or Nightmares |journal=Pharmacopsychiatry | volume=34 | issue=4 | pages=128–131 |year=2001 | doi=10.1055/s-2001-15871 | pmid=11518472 | postscript=<!-- Bot inserted parameter. Either remove it; or change its value to "." for the cite to end in a ".", as necessary. -->{{inconsistent citations}}}}
</ref>
* [[Panic disorder]]<ref>{{cite journal |author=Mavissakalian M, Perel J, Bowler K, Dealy R |title=Trazodone in the treatment of panic disorder and agoraphobia with panic attacks |journal=Am J Psychiatry |volume=144 |issue=6 |pages=785–7 |date=June 1987|pmid=3296792 |url=http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=3296792|last2=Perel |last3=Bowler |last4=Dealy |doi=10.1176/ajp.144.6.785}}</ref>
* [[Diabetic neuropathy]]<ref name="Rickels K, Downing R, Schweizer E, Hassman H 1993 884–95">{{cite journal |author=Rickels K, Downing R, Schweizer E, Hassman H |title=Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam |journal=Arch. Gen. Psychiatry |volume=50 |issue=11 |pages=884–95 |date=November 1993|pmid=8215814 |doi=10.1001/archpsyc.1993.01820230054005 |last2=Downing |last3=Schweizer |last4=Hassman }}</ref>
* [[Bulimia nervosa]]<ref>{{cite journal |author=Pope HG, Keck PE, McElroy SL, Hudson JI |title=A placebo-controlled study of trazodone in bulimia nervosa |journal=J Clin Psychopharmacol |volume=9 |issue=4 |pages=254–9 |date=August 1989|pmid=2671058 |doi=10.1097/00004714-198908000-00004 |last2=Keck Jr |last3=McElroy |last4=Hudson }}</ref>
* [[Obsessive-compulsive disorder]] (OCD)<ref>{{cite journal |author=Prasad A |title=Efficacy of trazodone as an anti obsessional agent |journal=Pharmacol. Biochem. Behav. |volume=22 |issue=2 |pages=347–8 |date=February 1985|pmid=3983224 |url=http://linkinghub.elsevier.com/retrieve/pii/0091-3057(85)90403-4 |doi=10.1016/0091-3057(85)90403-4}}</ref><ref name="Pigott TA, L'Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL 1992 156–62">{{cite journal |author=Pigott TA, L'Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL |title=A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder |journal=J Clin Psychopharmacol |volume=12 |issue=3 |pages=156–62 |date=June 1992|pmid=1629380 |doi=10.1097/00004714-199202000-00003 |last2=l'Heureux |last3=Rubenstein |last4=Bernstein |last5=Hill |last6=Murphy }}</ref>
* [[Alcohol withdrawal]]<ref>{{cite journal|author=Roccatagliata G |author2=Albano C |author3=Maffini M |author4=Farelli S |title=Alcohol withdrawal syndrome: treatment with trazodone |journal=Int Pharmacopsychiatry |year=1980 |volume=15 |issue=2 |pages=105–10 |pmid=6108298}}</ref><ref>{{cite journal |author=Le Bon O |author2=Murphy JR |author3=Staner L |author4=Hoffmann G |author5=Kormoss N |author6=Kentos M |author7=Dupont P |author8=Lion K |author9=Pelc I |author10=Verbanck P |title=Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations |journal=J Clin Psychopharmacol |date=August 2003 |volume=23 |issue=4 |pages=377–83 |pmid=12920414 |doi=10.1097/01.jcp.0000085411.08426.d3}}</ref><ref>{{cite journal |author=Borras L |author2=de Timary P |author3=Constant EL |author4=Huguelet P |author5=Eytan A |title=Successful treatment of alcohol withdrawal with trazodone |journal=Pharmacopsychiatry |date=November 2006 |volume=39 |issue=6 |page=232 |pmid=17124647 |doi=10.1055/s-2006-951385}}</ref>
* [[Schizophrenia]] as an adjunct to improve negative symptoms<ref>{{cite journal|last=Singh|first=SP|author2=Singh, V |author3=Kar, N |author4= Chan, K |title=Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis|journal=The British Journal of Psychiatry|year=2010|volume=197|issue=3|pages=174–179|doi=10.1192/bjp.bp.109.067710|pmid=20807960|url=http://bjp.rcpsych.org/content/197/3/174.full.pdf}}</ref>
* [[Erectile dysfunction]]<ref>{{cite journal|last=Fink|first=HA|author2=MacDonald, R |author3=Rutks, IR |author4= Wilt, TJ |title=Trazodone for erectile dysfunction: a systematic review and meta-analysis.|journal=BJU International|date=September 2003|volume=92|issue=4|pages=441–446|doi=10.1046/j.1464-410X.2003.04358.x|pmid=12930437|url=http://onlinelibrary.wiley.com/doi/10.1046/j.1464-410X.2003.04358.x/pdf}}</ref>

==Adverse effects==
{{See also|List of adverse effects of trazodone}}

Because of its lack of [[anticholinergic]] side effects, trazodone is especially useful in situations in which [[antimuscarinic]] effects are particularly problematic (e.g., in patients with benign prostatic hyperplasia, closed-angle glaucoma, or severe constipation). Trazodone's propensity to cause sedation is a dual-edged sword. For many patients, the relief from agitation, anxiety, and insomnia can be rapid; for other patients, including those individuals with considerable [[psychomotor retardation]] and feelings of low energy, therapeutic doses of trazodone may not be tolerable because of sedation. Trazodone elicits [[orthostatic hypotension]] in some patients, probably as a consequence of α<sub>1</sub>-adrenergic receptor blockade. Mania has been observed in association with trazodone treatment, including in patients with bipolar disorder, as well as in patients with previous diagnoses of major depression.
Compared to the reversible MAOI antidepressant drug [[moclobemide]], significantly more impairment of vigilance occurs with trazodone.<ref>{{cite journal |last1=Wesnes |first1=KA |last2= Simpson |first2= PM |last3=Christmas |first3=L |last4=Anand |first4=R |last5=McClelland|first5=GR |year=1989 |title=The effects of moclobemide on cognition |journal=J. Neural Transm. Suppl. |volume=28 |pages=91–102 |pmid=2677245 }}</ref>

===Cardiac arrhythmia===
Case reports have noted cardiac arrhythmias emerging in relation to trazodone treatment, both in patients with pre-existing mitral valve prolapse and in patients with negative personal and family histories of cardiac disease.<ref name="ReferenceA">{{cite book |editor1-last=Schatzberg |editor1-first=AF |editor2-last=Nemeroff |editor2-first=CB |title=Textbook of Psychopharmacology |edition=4th |year=2009 |publisher= American Psychiatric Publishing|location=Washington, D.C. |isbn=978-1-58562-309-9}}</ref>

QT prolongation has been reported with trazodone therapy. Arrhythmia identified include isolated PVCs, ventricular couplets, and in two patients short episodes (three to four beats) of ventricular tachycardia. Several post-marketing reports have been made of arrhythmia in trazodone-treated patients who have pre-existing cardiac disease and in some patients who did not have pre-existing cardiac disease. Until the results of prospective studies are available, patients with pre-existing cardiac disease should be closely monitored, particularly for cardiac arrhythmias. Trazodone is not recommended for use during the initial recovery phase of myocardial infarction. Concomitant administration of drugs that prolong the QT interval or that are inhibitors of CYP3A4 may increase the risk of cardiac arrhythmia.{{Citation needed|date=September 2013}}

===Priapism===
A relatively rare, but dramatic, side effect associated with trazodone is [[priapism]], likely due to its antagonism at α-adrenergic receptors.<ref>{{cite journal |author=Abber, RE; |lastauthoramp=yes |year=1987 |title=Priapism induced by chlorpromazine and trazodone: mechanism of action|journal= J. Urol |volume=137 |issue=5 |pages=1039–1042 |pmid=3573170 |display-authors=etal}}</ref> More than 200 cases have been reported, and the manufacturer estimated that the incidence of any abnormal erectile function is about one in 6,000 male patients treated with trazodone. The risk for this side effect appears to be greatest during the first month of treatment at low dosages (i.e. &lt;150&nbsp;mg/day). Early recognition of any abnormal erectile function is important, including prolonged or inappropriate erections, and should prompt discontinuation of trazodone treatment. Clinical reports have also described trazodone-associated psychosexual side effects in women, including increased [[libido]], priapism of the clitoris, and [[spontaneous orgasm]]s.<ref name="ReferenceA" /><ref>{{cite journal |author1=Battaglia |author2=ven Turoli RE |title=Persistent genital arousal disorder and trazodone. 5555Morphometric and vascular modifications of the clitoris. A case report |journal=[[J Sex Med]] |volume=6|issue=10 |pages=2896–2900 |year=2009 |pmid=19674253 |doi=10.1111/j.1743-6109.2009.01418.x }}</ref>

===Other===
Rare cases of idiosyncratic [[hepatotoxicity]] have been observed, possibly due to the formation of reactive metabolites.<ref>{{cite journal |author=Kalgutkar AS, Henne KR, Lame ME|title=Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4|journal=Chem Biol Interact. |volume=155 |issue=1–2 |pages=10–20 |date=June 2005|pmid=15978881|doi=10.1016/j.cbi.2005.03.036 |url=http://linkinghub.elsevier.com/retrieve/pii/S0009-2797(05)00098-0|last2=Henne|last3=Lame|last4=Vaz|last5=Collin|last6=Soglia|last7=Zhao|last8=Hop}}</ref>

Elevated [[prolactin]] concentrations have been observed in patients taking trazodone.<ref>{{cite journal |author=Otani K, Yasui N, Kaneko S |title=Trazodone treatment increases plasma prolactin concentrations in depressed patients |journal=Int Clin Psychopharmacol |volume=10|issue=2 |pages=115–7 |date=June 1995|pmid=7673654 |doi=10.1097/00004850-199506000-00009 |last2=Yasui |last3=Kaneko |last4=Ishida |last5=Ohkubo |last6=Osanai |last7=Sugawara |last8=Fukushima }}</ref>

===Precautions===
* If the patient has a known [[hypersensitivity]] to trazodone
* If the patient is under 18 years of age and trazodone is combined with other antidepressant medications, it may increase the possibility of suicidal thoughts or actions.<ref>{{cite web|url=http://www.webmd.com/drugs/drug-11188-Trazodone+Oral.aspx?drugid=11188&drugname=Trazodone+Oral |title=Webmd.com |publisher=Webmd.com |accessdate=2014-03-14}}</ref>

Trazodone is metabolized by [[CYP3A4]], a liver enzyme.<ref name=Rotzinger/> Inhibition of this enzyme by various other substances may delay its degradation, leading to high blood levels of trazodone. CYP3A4 may be inhibited by many other medications, herbs, and foods, and as such, trazodone may [[drug interaction|interact]] with these substances.

The possibility of [[suicide]] in depressed patients remains during treatment and until significant remission occurs. The number of tablets prescribed at any one time should take into account this possibility, and patients with [[suicidal ideation]] should never have access to large quantities of trazodone.

Trazodone has been reported to cause seizures in a small number of patients who took it concurrently with medications to control seizures.

While trazodone is not a true member of the [[SSRI]] class of antidepressants, it does still share many properties of the SSRIs, especially the possibility of [[SSRI discontinuation syndrome|discontinuation syndrome]] if the medication is stopped too quickly.<ref>{{cite journal |author=Warner CH, Bobo W, Warner C, Reid S, Rachal J |title=Antidepressant discontinuation syndrome |journal=Am Fam Physician |volume=74 |issue=3 |pages=449–56|date=August 2006|pmid=16913164 |url=http://www.aafp.org/afp/20060801/449.html|last2=Bobo |last3=Warner |last4=Reid |last5=Rachal }}</ref> Care must, therefore, be taken when coming off the medication, usually by a gradual process of tapering down the dose over a period of time.

===Pregnancy and lactation===
Sufficient data in humans are lacking. Use should be justified by the severity of the condition to be treated.<ref>{{cite journal |last1=Einarson |first1=A |last2=Bonari |first2=L|last3= Voyer-Lavigne |first3=S |last4=Addis |first4=A |last5=Matsui |first5=D |last6=Johnson|first6=Y |last7=Koren |first7=G |date=March 2003 |title=A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy |journal=Can J Psychiatry |volume=48 |issue=2 |pages=106–110 |pmid=12655908}}</ref><ref>{{cite journal|last1=Verbeeck |first1=RK |last2=Ross |first2=SG |last3=McKenna |first3=EA |date=September 1986 |title=Excretion of trazodone in breast milk |journal=Br J Clin Pharmacol |volume=22|issue=3 |pages=367–370 |pmid=3768252 |doi=10.1111/j.1365-2125.1986.tb02903.x |pmc=1401139}}</ref>

===Occupational hazards===
Since trazodone may impair the mental and/or physical abilities required for performance of potentially hazardous tasks, such as operating an automobile or machinery, the patient should be cautioned not to engage in such activities while impaired.

==Overdose==
There are reported cases of high doses of trazodone precipitating [[serotonin syndrome]].<ref>{{Cite journal|title = Selective Serotonin Reuptake Inhibitor Toxicity|url = http://emedicine.medscape.com/article/821737-overview|date = 2014-02-26 <!-- -05:00 --> }}</ref> There are also reports of patients taking multiple SSRIs with trazodone and precipitating serotonin syndrome.<ref>{{Cite journal|title = Selective Serotonin Reuptake Inhibitor Toxicity|url = http://emedicine.medscape.com/article/821737-overview|date = 2014-02-26 <!-- -05:00 --> }}</ref>

===Signs and symptoms===
Trazodone appears to be relatively safer than [[Tricyclic antidepressant|TCAs]], [[MAOI]]s, and a few of the other [[second-generation antidepressant]]s in overdose situations, especially when it is the only agent taken. Fatalities are rare, and uneventful recoveries have been reported after ingestion of doses as high as 6,000–9,200&nbsp;mg. In one report, 9 of 294 cases of overdose were fatal, and all nine patients had also taken other central nervous system (CNS) depressants. When trazodone overdoses occur, clinicians should carefully monitor for [[hypotension]], a potentially serious toxic effect. In a report of a fatal trazodone overdose, [[torsades de pointes]] and complete [[atrioventricular block]] developed, along with subsequent multiple organ failure, with a trazodone plasma concentration of 25.4&nbsp;mg/L on admission.<ref name="Textbook of Psychopharmacology" /><ref>{{cite journal |author=Martínez MA, Ballesteros S, Sánchez de la Torre C, Almarza E |title=Investigation of a fatality due to trazodone poisoning: case report and literature review |journal=J Anal Toxicol |volume=29 |issue=4|pages=262–8 |year=2005 |pmid=15975258 |url=http://openurl.ingenta.com/content/nlm?genre=article&issn=0146-4760&volume=29&issue=4&spage=262&aulast=Martínez |author3=Sánchez de la Torre C |doi=10.1093/jat/29.4.262|last2=Ballesteros |last4=Almarza }}</ref><ref>{{cite journal |author=de Meester A, Carbutti G, Gabriel L, Jacques JM|title=Fatal overdose with trazodone: case report and literature review |journal=Acta Clin Belg |volume=56 |issue=4 |pages=258–61 |year=2001 |pmid=11603256 |doi=10.1179/acb.2001.038|last2=Carbutti |last3=Gabriel |last4=Jacques }}</ref><ref>{{cite journal|author=Rakel RE |title=The greater safety of trazodone over tricyclic antidepressant agents: 5-year experience in the United States |journal=Psychopathology |volume=20 |issue=Suppl 1|pages=57–63 |year=1987 |pmid=3321131 |doi=10.1159/000284524 }}</ref>

===Treatment===
There is no specific antidote for trazodone. Management of overdosage should, therefore, be symptomatic and supportive. Any person suspected of having taken an overdosage should be evaluated at a hospital as soon as possible. [[Activated charcoal]], and [[forced diuresis]] may be useful in facilitating elimination of the drug, gastric lavage has been shown to not be useful unless done during the first hour after intake.{{citation needed|date=February 2016|reason=Entire paragraph needs sourcing}}

==Pharmacology==

===Pharmacodynamics===
{| class="wikitable floatright" style="font-size:small;"
|+ Trazodone (and metabolite)<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | accessdate = 14 August 2017 | url = https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=trazodone&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref>
|-
! Site !! Trazodone !! {{abbrlink|mCPP|meta-Chlorophenylpiperazine}} !! Species !! Ref
|-
| '''{{abbrlink|SERT|Serotonin transporter}}''' || '''160–367''' || '''202–432''' || '''Human''' || <ref name="PDSP" /><ref name="pmid9400006">{{cite journal | vauthors = Owens MJ, Morgan WN, Plott SJ, Nemeroff CB | title = Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites | journal = J. Pharmacol. Exp. Ther. | volume = 283 | issue = 3 | pages = 1305–22 | year = 1997 | pmid = 9400006 | doi = | url = }}</ref><ref name="pmid9537821">{{cite journal | vauthors = Tatsumi M, Groshan K, Blakely RD, Richelson E | title = Pharmacological profile of antidepressants and related compounds at human monoamine transporters | journal = Eur. J. Pharmacol. | volume = 340 | issue = 2-3 | pages = 249–58 | year = 1997 | pmid = 9537821 | doi = | url = }}</ref>
|-
| {{abbrlink|NET|Norepinephrine transporter}} || ≥8,500 || ≥1,940 || Human || <ref name="pmid9537821" /><ref name="pmid9400006" />
|-
| {{abbrlink|DAT|Dopamine transporter}} || ≥7,400 || {{abbr|ND|No data}} || Human || <ref name="pmid9537821" /><ref name="PDSP" />
|-
| '''[[5-HT1A receptor|5-HT<sub>1A</sub>]]''' || '''96–118''' || '''44–400''' || '''Human''' || <ref name="PDSP" /><ref name="pmid7855217">{{cite journal | vauthors = Cusack B, Nelson A, Richelson E | title = Binding of antidepressants to human brain receptors: focus on newer generation compounds | journal = Psychopharmacology | volume = 114 | issue = 4 | pages = 559–65 | year = 1994 | pmid = 7855217 | doi = | url = }}</ref><ref name="pmid2537663">{{cite journal | vauthors = Hamik A, Peroutka SJ | title = 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain | journal = Biol. Psychiatry | volume = 25 | issue = 5 | pages = 569–75 | year = 1989 | pmid = 2537663 | doi = | url = }}</ref>
|-
| '''[[5-HT1B receptor|5-HT<sub>1B</sub>]]''' || >10,000 || '''89–501''' || '''Human''' || <ref name="PDSP" /><ref name="pmid7984267">{{cite journal | vauthors = Boess FG, Martin IL | title = Molecular biology of 5-HT receptors | journal = Neuropharmacology | volume = 33 | issue = 3-4 | pages = 275–317 | year = 1994 | pmid = 7984267 | doi = | url = }}</ref>
|-
| '''[[5-HT1D receptor|5-HT<sub>1D</sub>]]''' || '''106''' || '''210–1,300''' || '''Human''' || <ref name="PDSP" /><ref name="pmid2537663" /><ref name="pmid1652050">{{cite journal | vauthors = Hamblin MW, Metcalf MA | title = Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor | journal = Mol. Pharmacol. | volume = 40 | issue = 2 | pages = 143–8 | year = 1991 | pmid = 1652050 | doi = | url = }}</ref>
|-
| [[5-HT1E receptor|5-HT<sub>1E</sub>]] || >10,000 || {{abbr|ND|No data}} || Human || <ref name="PDSP" />
|-
| [[5-HT1F receptor|5-HT<sub>1F</sub>]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| '''[[5-HT2A receptor|5-HT<sub>2A</sub>]]''' || '''20–45''' || '''32–398''' || '''Human''' || <ref name="PDSP" /><ref name="pmid15322733">{{cite journal | vauthors = Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M | title = Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors | journal = Naunyn Schmiedebergs Arch. Pharmacol. | volume = 370 | issue = 2 | pages = 114–23 | year = 2004 | pmid = 15322733 | doi = 10.1007/s00210-004-0951-4 | url = }}</ref><ref name="pmid7582481">{{cite journal | vauthors = Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, Eglen RM | title = The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors | journal = Br. J. Pharmacol. | volume = 115 | issue = 4 | pages = 622–8 | year = 1995 | pmid = 7582481 | pmc = 1908489 | doi = | url = }}</ref><ref name="pmid19505264">{{cite journal | vauthors = Rothman RB, Baumann MH | title = Serotonergic drugs and valvular heart disease | journal = Expert Opin Drug Saf | volume = 8 | issue = 3 | pages = 317–29 | year = 2009 | pmid = 19505264 | pmc = 2695569 | doi = 10.1517/14740330902931524 | url = }}</ref>
|-
| '''[[5-HT2B receptor|5-HT<sub>2B</sub>]]''' || '''74–189''' || '''3.2–63''' || '''Human''' || <ref name="PDSP" /><ref name="pmid15322733" /><ref name="pmid11104741">{{cite journal | vauthors = Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL | title = Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications | journal = Circulation | volume = 102 | issue = 23 | pages = 2836–41 | year = 2000 | pmid = 11104741 | doi = | url = }}</ref><ref name="pmid10498829">{{cite journal | vauthors = Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ | title = Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells | journal = Br. J. Pharmacol. | volume = 128 | issue = 1 | pages = 13–20 | year = 1999 | pmid = 10498829 | pmc = 1571597 | doi = 10.1038/sj.bjp.0702751 | url = }}</ref>
|-
| '''[[5-HT2C receptor|5-HT<sub>2C</sub>]]''' || '''224–402''' || '''3.4–251''' || '''Human''' || <ref name="pmid15322733" /><ref name="pmid15081042">{{cite journal | vauthors = Bentley JM, Adams DR, Bebbington D, Benwell KR, Bickerdike MJ, Davidson JE, Dawson CE, Dourish CT, Duncton MA, Gaur S, George AR, Giles PR, Hamlyn RJ, Kennett GA, Knight AR, Malcolm CS, Mansell HL, Misra A, Monck NJ, Pratt RM, Quirk K, Roffey JR, Vickers SP, Cliffe IA | title = Indoline derivatives as 5-HT(2C) receptor agonists | journal = Bioorg. Med. Chem. Lett. | volume = 14 | issue = 9 | pages = 2367–70 | year = 2004 | pmid = 15081042 | doi = 10.1016/j.bmcl.2003.05.001 | url = }}</ref><ref name="pmid9225287">{{cite journal | vauthors = Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM | title = RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist | journal = Neuropharmacology | volume = 36 | issue = 4-5 | pages = 621–9 | year = 1997 | pmid = 9225287 | doi = | url = }}</ref><ref name="pmid19505264" />
|-
| [[5-HT3 receptor|5-HT<sub>3</sub>]] || >10,000 || 427 || Human || <ref name="PDSP" />
|-
| [[5-HT4 receptor|5-HT<sub>4</sub>]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[5-HT5A receptor|5-HT<sub>5A</sub>]] || >10,000 || 1,354 || Human || <ref name="PDSP" />
|-
| [[5-HT6 receptor|5-HT<sub>6</sub>]] || >10,000 || 1,748 || Human || <ref name="PDSP" />
|-
| '''[[5-HT7 receptor|5-HT<sub>7</sub>]]''' || 1,782 || '''163''' || '''Human''' || <ref name="PDSP" />
|-
| '''[[Alpha-1 adrenergic receptor|α<sub>1</sub>]]''' || '''12–42''' || '''97–2,900''' || '''Human''' || <ref name="pmid9400006" /><ref name="pmid7855217" /><ref name="pmid2537663" /><ref name="pmid6086881">{{cite journal | vauthors = Richelson E, Nelson A | title = Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro | journal = J. Pharmacol. Exp. Ther. | volume = 230 | issue = 1 | pages = 94–102 | year = 1984 | pmid = 6086881 | doi = | url = }}</ref>
|-
| '''&nbsp;&nbsp;[[Alpha-1A adrenergic receptor|α<sub>1A</sub>]]''' || '''153''' || '''1,386''' || '''Human''' || <ref name="PDSP" />
|-
| &nbsp;&nbsp;[[Alpha-1B adrenergic receptor|α<sub>1B</sub>]] || {{abbr|ND|No data}} || 915 || Human || <ref name="PDSP" />
|-
| &nbsp;&nbsp;[[Alpha-1D adrenergic receptor|α<sub>1D</sub>]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| '''[[Alpha-2 adrenergic receptor|α<sub>2</sub>]]''' || '''106–490''' || '''112–570''' || '''Human''' || <ref name="pmid7855217" /><ref name="pmid9400006" /><ref name="pmid2537663" /><ref name="pmid6086881" />
|-
| '''&nbsp;&nbsp;[[Alpha-2A adrenergic receptor|α<sub>2A</sub>]]''' || 728 || '''145''' || '''Human''' || <ref name="PDSP" />
|-
| '''&nbsp;&nbsp;[[Alpha-2B adrenergic receptor|α<sub>2B</sub>]]''' || {{abbr|ND|No data}} || '''106''' || '''Human''' || <ref name="PDSP" />
|-
| '''&nbsp;&nbsp;[[Alpha-2C adrenergic receptor|α<sub>2C</sub>]]''' || '''155''' || '''124''' || '''Human''' || <ref name="PDSP" />
|-
| [[Beta adrenergic receptor|β]] || >10,000 || 2,500 || Human || <ref name="PDSP" /><ref name="pmid2537663"/>
|-
| &nbsp;&nbsp;[[Beta-1 adrenergic receptor|β<sub>1</sub>]] || >10,000 || 2,359 || Human || <ref name="PDSP" />
|-
| &nbsp;&nbsp;[[Beta-2 adrenergic receptor|β<sub>2</sub>]] || >10,000 || 3,474 || Human || <ref name="PDSP" />
|-
| [[Dopamine D1 receptor|D<sub>1</sub>]] || 3,730 || 7,000 || Human || <ref name="PDSP" /><ref name="pmid2537663" />
|-
| [[Dopamine D2 receptor|D<sub>2</sub>]] || ≥3,500 || >10,000 || Human || <ref name="PDSP" /><ref name="pmid7855217" /><ref name="pmid8100134" /><ref name="pmid2537663" />
|-
| [[Dopamine D3 receptor|D<sub>3</sub>]] || 353 || >10,000 || Rat || <ref name="PDSP" /><ref name="pmid2537663" />
|-
| [[Dopamine D4 receptor|D<sub>4</sub>]] || 703 || {{abbr|ND|No data}} || Human || <ref name="PDSP" />
|-
| [[Dopamine D5 receptor|D<sub>5</sub>]] || >10,000 || >10,000 || Human || <ref name="PDSP" /><ref name="pmid2537663" />
|-
| '''[[Histamine H1 receptor|H<sub>1</sub>]]''' || '''220–1,100''' || '''326''' || '''Human''' || <ref name="PDSP" /><ref name="pmid6086881" /><ref name="pmid7855217" />
|-
| [[Histamine H2 receptor|H<sub>2</sub>]] || 3,290 || {{abbr|ND|No data}} || Human || <ref name="PDSP" />
|-
| [[Histamine H3 receptor|H<sub>3</sub>]] || >10,000 || {{abbr|ND|No data}} || Guinea pig || <ref name="PDSP" />
|-
| [[Histamine H4 receptor|H<sub>4</sub>]] || >10,000 || {{abbr|ND|No data}} || Human || <ref name="PDSP" />
|-
| {{abbrlink|mAChRs|Muscarinic acetylcholine receptors}} || >10,000 || >10,000 || Human || <ref name="PDSP" /><ref name="pmid8100134">{{cite journal | vauthors = Stanton T, Bolden-Watson C, Cusack B, Richelson E | title = Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics | journal = Biochem. Pharmacol. | volume = 45 | issue = 11 | pages = 2352–4 | year = 1993 | pmid = 8100134 | doi = | url = }}</ref><ref name="pmid7855217" /><ref name="pmid2537663" />
|-
| {{abbrlink|nAChRs|Nicotinic acetylcholine receptors}} || >10,000 || >10,000 || Human || <ref name="PDSP" />
|-
| [[Sigma-1 receptor|σ<sub>1</sub>]] || >10,000 || {{abbr|ND|No data}} || Rat || <ref name="PDSP" />
|-
| [[Sigma-2 receptor|σ<sub>2</sub>]] || 536 || 8,350 || Rat || <ref name="PDSP" />
|-
| [[Imidazoline receptor|I<sub>1</sub>]] || {{abbr|ND|No data}} || 759 || Rat || <ref name="PDSP" />
|-
| [[NMDA receptor|{{abbr|NMDAR|N-Methyl-D-aspartate receptor}}<br />(MK-801)]] || >10,000 || {{abbr|ND|No data}} || Rat || <ref name="PDSP" />
|-
| {{abbrlink|VDCCs|Voltage-dependent calcium channels}} || >10,000 || 6,043 || Rat || <ref name="PDSP" />
|- class="sortbottom"
| colspan="5" style="width: 1px;" | Values are K<sub>i</sub> (nM). The smaller the value, the more strongly the drug binds to the site.
|}

Trazodone is generally described as acting as a [[potency (pharmacology)|potent]] [[serotonin]] [[5-HT2A receptor|5-HT<sub>2A</sub>]] and [[alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic receptor]] [[receptor antagonist|antagonist]], a weak [[serotonin reuptake inhibitor]] (SRI), and a weak [[antihistamine]] or [[histamine]] [[H1 receptor|H<sub>1</sub> receptor]] [[inverse agonist]].<ref name="pmid23192413">{{cite journal | vauthors = Fagiolini A, Comandini A, Catena Dell'Osso M, Kasper S | title = Rediscovering trazodone for the treatment of major depressive disorder | journal = CNS Drugs | volume = 26 | issue = 12 | pages = 1033–49 | year = 2012 | pmid = 23192413 | pmc = 3693429 | doi = 10.1007/s40263-012-0010-5 | url = }}</ref> Its 5-HT<sub>2A</sub> receptor antagonism and weak serotonin reuptake inhibition form the basis of its common label as a [[serotonin antagonist and reuptake inhibitor]] (SARI).<ref name="pmid27744763">{{cite journal | vauthors = Khouzam HR | title = A review of trazodone use in psychiatric and medical conditions | journal = Postgrad Med | volume = 129 | issue = 1 | pages = 140–148 | year = 2017 | pmid = 27744763 | doi = 10.1080/00325481.2017.1249265 | url = }}</ref> Trazodone, both itself and via its major [[active metabolite]] [[meta-chlorophenylpiperazine|''meta''-chlorophenylpiperazine]] (mCPP),<ref name="LemkeWilliams2008">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA586|year=2008|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-6879-5|pages=586–}}</ref> also binds to a variety of other receptors.<ref name="PDSP" /> It is an [[receptor antagonist|antagonist]] at most or all of the receptors it binds to except the [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]], where it acts as a [[partial agonist]] similarly to [[buspirone]] and [[tandospirone]] but with comparatively greater [[intrinsic activity]].<ref name="PDSP" /><ref name="pmid1387963">{{cite journal | author = Raffa RB, Shank RP, Vaught JL | title = Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity | journal = Psychopharmacology | volume = 108 | issue = 3 | pages = 320–6 | year = 1992 | pmid = 1387963 | doi = 10.1007/BF02245118| url = | last2 = Shank | last3 = Vaught }}</ref><ref name="pmid15888508">{{cite journal | author = Odagaki Y, Toyoshima R, Yamauchi T | title = Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding | journal = Journal of Psychopharmacology (Oxford, England) | volume = 19 | issue = 3 | pages = 235–41 |date=May 2005 | pmid = 15888508 | doi = 10.1177/0269881105051526 | url = http://jop.sagepub.com/cgi/pmidlookup?view=long&pmid=15888508| last2 = Toyoshima | last3 = Yamauchi }}</ref> Conversely, mCPP is a non-selective [[agonist]] of most of the [[serotonin receptor]]s it binds to.<ref name="pmid1663792">{{cite journal | vauthors = Kahn RS, Wetzler S | title = m-Chlorophenylpiperazine as a probe of serotonin function | journal = Biol. Psychiatry | volume = 30 | issue = 11 | pages = 1139–66 | year = 1991 | pmid = 1663792 | doi = | url = }}</ref> A range of weak affinities (K<sub>i</sub>) have been reported for trazodone at the human [[histamine]] [[H1 receptor|H<sub>1</sub> receptor]] including 220&nbsp;nM,<ref name="PDSP" /> 350&nbsp;nM,<ref name="pmid6086881" /> 500&nbsp;nM,<ref name="pmid23357028">{{cite journal | vauthors = Krystal AD, Richelson E, Roth T | title = Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications | journal = Sleep Med Rev | volume = 17 | issue = 4 | pages = 263–72 | year = 2013 | pmid = 23357028 | doi = 10.1016/j.smrv.2012.08.001 | url = }}</ref> and 1,100&nbsp;nM.<ref name="pmid7855217" />

====Correspondence to clinical effects====
Trazodone acts predominantly as a 5-HT<sub>2A</sub> receptor antagonist to mediate its therapeutic benefits against [[anxiety]] and [[major depression|depression]].<ref name="pmid1365657">{{cite journal |author=Marek GJ, McDougle CJ, Price LH, Seiden LS |title=A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action |journal=Psychopharmacology |volume=109 |issue=1–2 |pages=2–11 |year=1992 |pmid=1365657 |doi=10.1007/BF02245475 |last2=McDougle |last3=Price |last4=Seiden}}</ref> Its inhibitory effects on serotonin reuptake and 5-HT<sub>2C</sub> receptors are comparatively weak.<ref name="pmid1365657"/> Hence, trazodone does not have similar properties to [[selective serotonin reuptake inhibitor]]s (SSRIs)<ref name="pmid1365657"/> and is not particularly associated with increased [[appetite]] and [[weight gain]], unlike other 5-HT<sub>2C</sub> antagonists like [[mirtazapine]].<ref name="pmid12096167">{{cite journal |vauthors=Vanina Y, Podolskaya A, Sedky K |title=Body weight changes associated with psychopharmacology |journal=Psychiatric Services |location=Washington, D.C. |volume=53 |issue=7 |pages=842–7 |date=July 2002 |pmid=12096167 |doi=10.1176/appi.ps.53.7.842|url=http://ps.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=12096167|display-authors=etal}}</ref><ref name="pmid20030418">{{cite journal |vauthors=Watanabe N, Omori IM, Nakagawa A |title=Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis |journal=CNS Drugs |volume=24 |issue=1 |pages=35–53 |date=January 2010 |pmid=20030418 |doi=10.2165/11319480-000000000-00000 |url=http://content.wkhealth.com/linkback/openurl?issn=1172-7047&volume=24&issue=1&spage=35|display-authors=etal}}</ref> Moderate 5-HT<sub>1A</sub> partial agonism is likely to contribute to trazodone's antidepressant and anxiolytic actions to some extent as well.<ref name="pmid1387963"/><ref name="pmid15888508"/><ref name="pmid10065919">{{cite journal |author=Kinney GG, Griffith JC, Hudzik TJ |title=Antidepressant-like effects of 5-hydroxytryptamine1A receptor agonists on operant responding under a response duration differentiation schedule |journal=Behavioural Pharmacology |volume=9 |issue=4 |pages=309–18 |date=July 1998 |pmid=10065919 |doi=10.1097/00008877-199807000-00002 |last2=Griffith |last3=Hudzik}}</ref>

The combined actions of 5-HT<sub>2A</sub> and 5HT<sub>2C</sub> receptor antagonism with serotonin reuptake inhibition only occur at moderate to high doses of trazodone.<ref name="Stahl2013">{{cite book |last=Stahl |first=S.M. |title=Stahl’s Essential Psychopharmacology|edition=4th |year=2013 |publisher=Cambridge University Press |isbn=1107686466 }}</ref> Doses of trazodone lower than those effective for antidepressant action are frequently used for the effective treatment of insomnia.<ref name="Stahl2013" /> Low doses exploit trazodone's potent actions as a 5-HT<sub>2A</sub> receptor antagonist, and its properties as an antagonist of H<sub>1</sub> and α<sub>1</sub>-adrenergic receptors, but do not adequately exploit its SERT or 5-HT<sub>2C</sub> inhibition properties, which are weaker.<ref name="Stahl2013" /> Since insomnia is one of the most frequent residual symptoms of depression after treatment with an SSRI, a hypnotic is often necessary for patients with a major depressive episode.<ref name="Stahl2013" /> Not only can a hypnotic potentially relieve the insomnia itself, but treating insomnia in patients with major depression may also increase remission rates due to improvement of other symptoms such as loss of energy and depressed mood.<ref name="Stahl2013" /> Thus, the ability of low doses of trazodone to improve sleep in depressed patients may be an important mechanism whereby trazodone can augment the efficacy of other antidepressants.<ref name="Stahl2013" />

Trazodone's potent α<sub>1</sub>-adrenergic blockade may cause some [[side effect]]s like [[orthostatic hypotension]] and [[sedation]].<ref name="pmid3802006">{{cite journal | author = Asayesh K | title = Combination of trazodone and phenothiazines: a possible additive hypotensive effect | journal = Canadian Journal of Psychiatry | volume = 31 | issue = 9 | pages = 857–8 |date=December 1986 | pmid = 3802006 | doi = | url = }}</ref> Conversely, along with 5-HT<sub>2A</sub> and H<sub>1</sub> receptor antagonism, it may contribute to its efficacy as a [[hypnotic]]. Trazodone lacks any affinity for the [[muscarinic acetylcholine receptor]]s, so does not produce [[anticholinergic]] side effects.

mCPP, a non-selective [[serotonin receptor]] [[receptor modulator|modulator]] and [[serotonin releasing agent]], is the major active metabolite of trazodone and has been suggested to possibly play a role in its therapeutic benefits.<ref name="pmid7255270">{{cite journal |title=Preliminary study of the biotransformation of two new drugs, trazodone and etoperidone |journal=Polish Journal of Pharmacology and Pharmacy |volume=32 |issue=4 |pages=551–6 |year=1980 |pmid=7255270 |last2=Rurak |last3=Vetulani |name-list-format=vanc|author1=Melzacka M}}</ref><ref name="pmid6128394">{{cite journal |author=Fong MH, Garattini S, Caccia S |title=1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole |journal=The Journal of Pharmacy and Pharmacology |volume=34 |issue=10 |pages=674–75 |date=October 1982 |pmid=6128394 |doi=10.1111/j.2042-7158.1982.tb04701.x |last2=Garattini |last3=Caccia}}</ref><ref name="pmid9315986">{{cite journal |vauthors=Maes M, Westenberg H, Vandoolaeghe E |title=Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine |journal=Journal of Clinical Psychopharmacology |volume=17 |issue=5 |pages=358–64 |date=October 1997 |pmid=9315986 |doi=10.1097/00004714-199710000-00004|url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0271-0749&volume=17&issue=5&spage=358|display-authors=etal}}</ref> However, scientific research has not supported this hypothesis, and mCPP may actually antagonize trazodone's efficacy as well as produce additional side effects.<ref name="pmid12142643">{{cite journal |vauthors=Mihara K, Yasui-Furukori N, Kondo T |title=Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients |journal=Therapeutic Drug Monitoring |volume=24 |issue=4 |pages=563–6 |date=August 2002 |pmid=12142643 |doi=10.1097/00007691-200208000-00016|url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0163-4356&volume=24&issue=4&spage=563|display-authors=etal}}</ref><ref name="pmid2311675">{{cite journal |author=Li AA, Marek GJ, Hand TH, Seiden LS |title=Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite m-chlorophenylpiperazine |journal=European Journal of Pharmacology |volume=177 |issue=3 |pages=137–144 |date=February 1990 |pmid=2311675 |doi=10.1016/0014-2999(90)90263-6|last2=Marek |last3=Hand |last4=Seiden}}</ref><ref name="pmid6431467">{{cite journal |author=Vetulani J, Sansone M, Baran L, Hano J |title=Opposite action of m-chlorophenylpiperazine on avoidance depression induced by trazodone and pimozide in CD-1 mice |journal=Psychopharmacology |volume=83 |issue=2 |pages=166–8 |year=1984 |pmid=6431467 |doi=10.1007/BF00429728|url=|last2=Sansone |last3=Baran |last4=Hano }}</ref><ref name="pmid19384678">{{cite journal |author=Kast RE |title=Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone |journal=World Journal of Biological Psychiatry |volume=10 |issue=4 Pt 2 |pages=682–5 |year=2009 |pmid=19384678 |doi=10.1080/15622970902836022 |url=http://informahealthcare.com/doi/abs/10.1080/15622970902836022}}</ref><ref name="pmid1575270">{{cite journal |author=Workman EA, Tellian F, Short D |title=Trazodone induction of migraine headache through mCPP |journal=The American Journal of Psychiatry |volume=149 |issue=5 |page=712 |date=May 1992 |pmid=1575270 |doi=10.1176/ajp.149.5.712b |last2=Tellian |last3=Short}}</ref>

===Pharmacokinetics===
Trazodone is well absorbed after oral administration, with mean peak blood levels obtained at about one hour after ingestion. Absorption is somewhat delayed and enhanced by food. The mean blood elimination half-life is biphasic: the first phase's half-life is 3 to 6&nbsp;hours, and the following phase's half-life is 5 to 9&nbsp;hours. The drug is extensively metabolized, with three or four major metabolites having been identified in the human body, particularly [[1-(3-Chlorophenyl)piperazine|mCPP]],<ref name=Rotzinger>{{cite journal |author=Rotzinger S, Fang J, Baker GB |title=Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources |journal=Drug Metab. Dispos. |volume=26 |issue=6 |pages=572–5 |date=1 June 1998|pmid=9616194 |url=http://dmd.aspetjournals.org/cgi/content/full/26/6/572 |last2=Fang |last3=Baker }}</ref> which may contribute to the side effect profile of trazodone and which probably accounts for trazodone's serotonergic effects.<ref name=Garattini>{{cite journal|last1=Garattini|first1=S|title=Active drug metabolites. An overview of their relevance in clinical pharmacokinetics.|journal=Clinical pharmacokinetics|date=1985|volume=10|issue=3|pages=216–27|doi=10.2165/00003088-198510030-00002|pmid=2861928}}</ref> Trazodone levels are about 10-fold those of mCPP with treatment.<ref name="VazKlabunde2008">{{cite book|author1=Roy J. Vaz|author2=Thomas Klabunde|title=Antitargets: Prediction and Prevention of Drug Side Effects|url=https://books.google.com/books?id=oSnSk1kv0dAC&pg=PA149|date=9 April 2008|publisher=John Wiley & Sons|isbn=978-3-527-62147-7|pages=149–}}</ref>

Around 70 to 75% of <sup>14</sup>C-labelled trazodone was found to be excreted in the urine within 72&nbsp;hours.<ref>{{cite journal |author=Jauch R, Kopitar Z, Prox A, Zimmer A |title=[Pharmacokinetics and metabolism of trazodone in man (author's transl)] |language=German |journal=Arzneimittelforschung |volume=26 |issue=11 |pages=2084–9 |year=1976 |pmid=1037253 |trans_title=Pharmacokinetics and metabolism of trazodone in man (author's transl) |last2=Kopitar |last3=Prox |last4=Zimmer }}</ref> Trazodone is highly protein-bound.

As a consequence of the production of mCPP as a metabolite, patients administered trazodone may test positive on [[EMIT]] II urine tests for the presence of [[MDMA]] ("ecstasy").<ref>{{cite journal |author=Logan BK, Costantino AG, Rieders EF, Sanders D |title=Trazodone, meta-chlorophenylpiperazine (a hallucinogenic drug and trazodone metabolite), and the hallucinogen trifluoromethylphenylpiperazine cross-react with the EMIT®II ecstasy immunoassay in urine |journal=J Anal Toxicol |volume=34 |issue=9 |pages=587–9 |date=Nov 2010|pmid=21073812 |doi=10.1093/jat/34.9.587|last2=Costantino |last3=Rieders |last4=Sanders }}</ref>

==Chemistry==
Trazodone is a [[triazolopyridine]] derivative and a [[phenylpiperazine]] that is chemically related to [[nefazodone]] and [[etoperidone]], each of which are derivatives of it.<ref>{{cite book|last1=Akritopoulou-Zanze|first1=Irini|editor1-last=Dinges|editor1-first=Jürgen|editor2-last=Lamberth|editor2-first=Clemens|title=Bioactive heterocyclic compound classes pharmaceuticals|date=2012|publisher=Wiley-VCH|location=Weinheim|isbn=9783527664450|chapter=6. Arylpiperazine-Based 5-HT1A Receptor Partial Agonists and 5-HT2A Antagonists for the Treatment of Autism, Depression, Anxiety, Psychosis, and Schizophrenia}}</ref><ref>{{cite book|editor1-last=Dörwald|editor1-first=Florencioa Zaragoza|title=Lead optimization for medicinal chemists : pharmacokinetic properties of functional groups and organic compounds|date=2012|publisher=Wiley-VCH|location=Weinheim|isbn=9783527645640|chapter=46. Arylalkylamines}}</ref><ref>{{cite journal|last1=Haria|first1=M|last2=Fitton|first2=A|last3=McTavish|first3=D|title=Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.|journal=Drugs & aging|date=April 1994|volume=4|issue=4|pages=331–55|pmid=8019056}}</ref>

==History==
Trazodone was discovered in [[Italy]] in the 1960s by [[Angelini]] Research Laboratories as a second-generation [[antidepressant]].<ref>{{cite book|last1=Gorecki|first1=Dennis K.J.|last2=Verbeeck|first2=Roger K.|editor1-last=Forey|editor1-first=Klaus|title=Profiles of Drug Substances, Excipients and Related Methodology Vol. 16|date=1987|publisher=Academic Press|isbn=9780080861111|page=695|url=https://books.google.com/books?id=tQiZCwMb2jAC&pg=PA695|language=en|chapter=Trazondone Hydrochloride}}</ref><ref>{{cite web|last1=Wegener|first1=Gregers|title=Ban & Silvestrini’s Trazodone|url=http://inhn.org/books/books/ban-silvestrinis-trazodone.html|website=inhn.org|accessdate=4 June 2017|language=en|date=30 March 2016}}</ref> It was developed according to the [[Psychological pain|mental pain]] hypothesis, which was postulated from studying patients and which proposes that [[Major depressive disorder|major depression]] is associated with a decreased pain threshold.<ref>{{Cite journal |author=Silvestrini B |title=Trazodone: from the mental pain to the "dys-stress" hypothesis of depression |journal=Clin Neuropharmacol |volume=12 |issue=Suppl 1 |pages=S4–10|year=1989 |pmid=2568177 |doi=10.1097/00002826-198901001-00002 }}</ref> In sharp contrast to most other antidepressants available at the time of its development, trazodone showed minimal effects on muscarinic cholinergic receptors. Trazodone was patented and marketed in many countries all over the world. It was approved by the [[Food and Drug Administration]] (FDA) in 1981<ref>{{cite news|title=Trazodone: Common sleep drug is little-known antidepressant - Consumer Reports|url=http://www.consumerreports.org/cro/2012/04/trazodone-common-sleep-drug-is-little-known-antidepressant/index.htm|work=Consumer Reports|date=August 2015}}</ref> and was the first non-[[tricyclic antidepressant]] approved in the US.<ref>{{cite book|last1=Eisen|first1=Michael S.|last2=Taylor|first2=Duncan B.|last3=Riblet|first3=Leslie A.|editor1-last=Williams|editor1-first=Michael|editor2-last=Malick|editor2-first=Jeffrey B.|title=Drug Discovery and Development|date=2012|publisher=Springer Science & Business Media|isbn=9781461248286|page=388|url=https://books.google.com/books?id=O0LuBwAAQBAJ&pg=PA388|language=en|chapter=Atypical Psychotropic Agents}}</ref>

==References==
{{Reflist|30em}}

==External links==
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Trazodone U.S. National Library of Medicine: Drug Information Portal – Trazodone]

{{Navboxes
| title = [[Medicine|Medical uses]]
| titlestyle = background:#ccccff
| list1 = 
{{Antidepressants}}
{{Anxiolytics}}
{{Hypnotics}}
}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Histamine receptor modulators}}
{{Monoamine reuptake inhibitors}}
{{Serotonin receptor modulators}}
}}

[[Category:5-HT1A agonists]]
[[Category:5-HT2A antagonists]]
[[Category:Alpha-1 blockers]]
[[Category:Antidepressants]]
[[Category:Anxiolytics]]
[[Category:Chloroarenes]]
[[Category:H1 receptor antagonists]]
[[Category:Hypnotics]]
[[Category:Lactams]]
[[Category:Piperazines]]
[[Category:Serotonin reuptake inhibitors]]
[[Category:Triazolopyridines]]
[[Category:Ureas]]